{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:43:27Z","timestamp":1790934207605,"version":"4.1.0"},"reference-count":63,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3760,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,10]]},"abstract":"<jats:p>Nonsteroidal antiinflammatory drugs (NSAIDs) often are prescribed to patients who are taking concomitant drugs. Cyclooxygenase (COX)\u20102 inhibitors (coxibs) rofecoxib and celecoxib are highly selective inhibitors of COX\u20102, differentiating them from nonselective NSAIDs, which substantially inhibit both COX\u20101 and COX\u20102. Like nonselective NSAIDs, coxibs are hepatically metabolized: rofecoxib primarily by reduction by cytosolic enzymes and celecoxib by the cytochrome P450 (CYP) enzyme system. Because rofecoxib is not significantly metabolized by CYP, it has fewer confirmed or potential drug interactions than celecoxib. However, potent inducers of CYP, such as rifampin, may decrease rofecoxib concentrations because of induction of general hepatic metabolic activity. Celecoxib is metabolized by CYP2C9 and may be increased or decreased by CYP2C9 modifiers. It also inhibits CYP2D6 and may affect concentrations of CYP2D6 substrates. Similar to NSAIDs, many pharmacodynamic interactions involving coxibs are related to inhibition of production of renal prostaglandins. However, coxibs have no antiplatelet activity and may be preferred to NSAIDs in patients receiving antithrombotic therapy. Nonetheless, when a potential for an interaction exists, standard monitoring is recommended when starting or discontinuing a coxib. Due to lack of data to support these interactions, which are primarily theoretical, additional studies are necessary to establish the drug interaction profiles of coxibs.<\/jats:p>","DOI":"10.1592\/phco.21.15.1223.33891","type":"journal-article","created":{"date-parts":[[2004,6,4]],"date-time":"2004-06-04T05:56:42Z","timestamp":1086328602000},"page":"1223-1232","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Clinical Implications of Drug Interactions with Coxibs"],"prefix":"10.1002","volume":"21","author":[{"given":"William R.","family":"Garnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199427060-00005"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199710020-00005"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.50.10.680"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01630479"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.12.12.1063"},{"issue":"49","key":"e_1_2_1_7_2","first-page":"15","article-title":"COX\u20101 and COX\u20102 tissue expression: implications and predictions","volume":"24","author":"Crofford L.J.","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00115-1"},{"issue":"3","key":"e_1_2_1_9_2","first-page":"8","article-title":"Role of cyclooxygenase\u20101 and \u22122 in health and disease","volume":"28","author":"Lipsky P.E.","year":"1999","journal-title":"Am J Orthop"},{"issue":"56","key":"e_1_2_1_10_2","first-page":"31","article-title":"Update on clinical developments with celecoxib, a new specific COX\u20102 inhibitor: what can we expect?","volume":"26","author":"Geis G.S.","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0160-3450(15)31182-X","article-title":"NSAID adverse effects and interactions: who is at risk?","author":"Knodel L.C.","year":"1992","journal-title":"Am Pharm"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)12154-2"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059040-00017"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00364-2"},{"key":"e_1_2_1_15_2","volume-title":"Vioxx (rofecoxib) package insert","author":"Merck & Co., Inc.","year":"1999"},{"issue":"11","key":"e_1_2_1_16_2","first-page":"S617","article-title":"Sc\u201058635 (celecoxib): a highly selective inhibitor of cyclooxygenase\u20102. Disposition kinetics in man and identification of its major CYP 450 isozyme in its biotransformation [abstr]","volume":"14","author":"Karim A.","year":"1997","journal-title":"Pharm Res"},{"issue":"2","key":"e_1_2_1_17_2","first-page":"R509","article-title":"Influence of the selective cyclooxygenase\u20142 inhibitor, MK\u20100966 [MK], on cytochrome P50 [CYP] activity [abstr]","volume":"358","author":"Schwartz J.I.","year":"1998","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"e_1_2_1_18_2","volume-title":"Celebrex (celecoxib) package insert","author":"GD Searle & Co.","year":"1999"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03830.x"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809502900612"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199018030-00004"},{"key":"e_1_2_1_22_2","first-page":"9","article-title":"Role of the cytochrome P450 3A subfamily in drug interactions","author":"Cupp M.J.","year":"1997","journal-title":"US Pharmacist"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199806000-00001"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00721.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2890533"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(98)00133-6"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2001.00340.x"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.112.15"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01330.x"},{"key":"e_1_2_1_30_2","first-page":"11","article-title":"Celecoxib for arthritis","volume":"41","author":"Abramowicz M.","year":"1999","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP38069"},{"key":"e_1_2_1_32_2","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1001\/archinte.1997.00440420085007","article-title":"Update on rifampin drug interactions. III","volume":"157","author":"Strayhorn V.A.","year":"1997","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb03516.x"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050736"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90018-1"},{"key":"e_1_2_1_36_2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0090-9556(25)08424-7","article-title":"Theophylline N\u2010demethylations as probes for P4501A1 and P4501A2","volume":"22","author":"Sarkar M.A.","year":"1994","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-9556(25)08515-0"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.112244"},{"key":"e_1_2_1_39_2","unstructured":"SchwartzJ.I. MukhopadhyayS. PorrasA.G. EbelD.L. AdcockS. GertzB.J..Influence of a selective cyclooxygenase\u20102 (COX\u20102) inhibitor rofecoxib on prednisone and prednisolone plasma concentrations. Presented at the annual meeting of the European League against Rheumatism Glasgow Scotland June 611 1999."},{"key":"e_1_2_1_40_2","first-page":"203","article-title":"Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis","volume":"21","author":"Anaya J.M.","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600790907"},{"key":"e_1_2_1_42_2","first-page":"S579","article-title":"Comparison of toxicity in methotrexate (MTX) treated RA patients also taking aspirin or other NSAIDs [abstr]","volume":"26","author":"Rooney T.W.","year":"1986","journal-title":"Arthritis Rheum"},{"key":"e_1_2_1_43_2","first-page":"1008","article-title":"Lack of significant interaction between low dose methotrexate and ibuprofen in patients with arthritis","volume":"17","author":"Skeith K.J.","year":"1990","journal-title":"J Rheumatol"},{"issue":"22","key":"e_1_2_1_44_2","first-page":"16","article-title":"Drug\u2010drug interactions with antirheumatic agents: review of selected clinically important interactions","volume":"17","author":"Stewart C.F.","year":"1990","journal-title":"J Rheumatol Suppl"},{"key":"e_1_2_1_45_2","unstructured":"SchwartzJ.I. AgrawalN. WongP. et al.Rofecoxib up to 50 mg daily did not affect methotrexate plasma concentrations. Presented at the annual European congress of rheumatology Nice France June 2024 2000."},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390503"},{"key":"e_1_2_1_47_2","unstructured":"KarimA. TolbertD. PiergiesA. et al.Celecoxib a specific COX\u20102 inhibitor lacks significant drug\u2010drug interactions with methotrexate or warfarin two medications commonly used by arthritis patients. Presented at the 1998 national scientific meeting of the American College of Rheumatology San Diego November 812 1998."},{"key":"e_1_2_1_48_2","doi-asserted-by":"crossref","unstructured":"SchwartzJ.I. PorrasA. LarsonP. et al.Influence of antacids on the bioavailability of a specific cyclooxygenase (COX)\u20102 inhibitor MK\u20100966 (rofecoxib VIOXX) in the elderly. Presented at a meeting of the American Society of Clinical Pharmacology and Therapeutics San Antonio TX March 1820 1999.","DOI":"10.1016\/S0009-9236(99)80222-7"},{"key":"e_1_2_1_49_2","first-page":"A113","article-title":"Influence of a selective cyclooxygenase\u20102 inhibitor, MK\u20100966, on ethinyl estradiol (EE) and norethindrone (NET) serum concentrations [abstr]","volume":"52","author":"Schwartz J.","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"e_1_2_1_50_2","first-page":"F460","article-title":"Localization of cyclooxygenase\u20101 and \u22122 in adult and fetal human kidney: implication for renal function","volume":"272","author":"K\u00f6mhoff M.","year":"1997","journal-title":"Am J Physiol"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1177\/019262339802600116"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(99)01088-1"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01782978"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127000004001005"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111110"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)80184-2"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809502901214"},{"key":"e_1_2_1_59_2","unstructured":"BelloA..\u201cDear health care professional\u201d [letter]. Available fromhttp:www.fda.govmedwatchsafety1999celebr.htm. Accessed July 19 1999."},{"key":"e_1_2_1_60_2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/j.1552-4604.2000.tb05992.x","article-title":"Celecoxib does not significantly alter the pharmacokinetics or hypoprothrom\u2010binemic effect of warfarin in healthy subjects","volume":"20","author":"Karim A.","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1159\/000177507"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-4-199408150-00011"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1993.00410040045007"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90485-G"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.15.1223.33891","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.15.1223.33891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:03:14Z","timestamp":1761048194000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.15.1223.33891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,10]]}},"alternative-id":["10.1592\/phco.21.15.1223.33891"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.15.1223.33891","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,10]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}